Enveric Biosciences, a biotech company developing novel neuroplastogenic small-molecule therapies for psychiatric and neurological disorders, has secured a key US patent for its next-gen neuropsychiatric drugs.
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.” The patent protects compositions and treatment methods for new molecules with potential applications in mental health.
The patent strengthens Enveric’s pipeline of potentially neuroplastogenic, non-hallucinogenic molecules and expands the company’s ability to tackle neuropsychiatric, neurological, and addiction disorders for patients with limited options.
According to the company, the new molecules may target key receptors in novel ways, producing drug candidates with efficacy and safety profiles previously unattainable. The expanded portfolio also opens doors for licensing and partnerships with pharmaceutical companies investing in neuropsychiatric therapies.
“Enveric’s growing pipeline of patented molecules expands the available opportunities to develop next-generation treatments for neuropsychiatric conditions, leveraging our innovative research,” said Joseph Tucker, Director and CEO of Enveric.
“As our intellectual property footprint and portfolio of patented molecules expand, the impact of our efforts is crystalizing into a significant position within the overall industry, providing the…”
Strong intellectual property protection, including composition-of-matter coverage as in the new patent, is critical to supporting comprehensive clinical development programs and ensuring a viable return on investment.
The molecules in the 179 patent are chemically modified versions of known compounds, designed to improve efficacy and minimize side effects. Enveric says these novel compounds have the potential to outperform existing treatments for neuropsychiatric conditions.
,_Thyrocare.jpg)
